E-viri
PDF
Recenzirano
Odprti dostop
-
Metra, Marco; Teerlink, John R; Cotter, Gad; Davison, Beth A; Felker, G. Michael; Filippatos, Gerasimos; Greenberg, Barry H; Pang, Peter S; Ponikowski, Piotr; Voors, Adriaan A; Adams, Kirkwood F; Anker, Stefan D; Arias-Mendoza, Alexandra; Avendaño, Patricio; Bacal, Fernando; Böhm, Michael; Bortman, Guillermo; Cleland, John G.F; Cohen-Solal, Alain; Crespo-Leiro, Maria G; Dorobantu, Maria; Echeverría, Luis E; Ferrari, Roberto; Goland, Sorel; Goncalvesová, Eva; Goudev, Assen; Køber, Lars; Lema-Osores, Juan; Levy, Phillip D; McDonald, Kenneth; Manga, Pravin; Merkely, Béla; Mueller, Christian; Pieske, Burkert; Silva-Cardoso, Jose; Špinar, Jindřich; Squire, Iain; Stępińska, Janina; Van Mieghem, Walter; von Lewinski, Dirk; Wikström, Gerhard; Yilmaz, Mehmet B; Hagner, Nicole; Holbro, Thomas; Hua, Tsushung A; Sabarwal, Shalini V; Severin, Thomas; Szecsödy, Peter; Gimpelewicz, Claudio
The New England journal of medicine, 08/2019, Letnik: 381, Številka: 8Journal Article
In a randomized trial, 6545 patients with acute heart failure were assigned to either serelaxin or placebo in addition to standard care. There were no significant differences between the two groups in the incidence of death from cardiovascular causes at 180 days or worsening heart failure at 5 days.
